MedPath

Cinacalcet

Generic Name
Cinacalcet
Brand Names
Mimpara, Sensipar, Cinacalcet Mylan, Cinacalcet Accordpharma
Drug Type
Small Molecule
Chemical Formula
C22H22F3N
CAS Number
226256-56-0
Unique Ingredient Identifier
UAZ6V7728S
Background

Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.

Indication

For the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease who are on hemodialysis or peritoneal dialysis. Also for the treatment of hypercalcemia in patients with parathyroid carcinoma.

Associated Conditions
Hypercalcemia, Secondary Hyperparathyroidism (SHPT)
Clinical Trials
Related News

Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis

Phase 4
Completed
Conditions
Hyperparathyroidism, Secondary
Interventions
Drug: Traditional Vitamin D Therapy
First Posted Date
2010-08-13
Last Posted Date
2018-10-17
Lead Sponsor
Amgen
Target Recruit Count
312
Registration Number
NCT01181531

Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation

Phase 4
Completed
Conditions
Secondary Hyperparathyroidism
Interventions
Procedure: Subtotal parathyroidectomy
First Posted Date
2010-08-10
Last Posted Date
2015-04-28
Lead Sponsor
Josep M Cruzado
Target Recruit Count
30
Registration Number
NCT01178450
Locations
🇪🇸

Hospital Clinic de Barcelona, Barcelona, Spain

🇪🇸

Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelone, Spain

Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism

Phase 4
Completed
Conditions
Hyperparathyroidism
Arterial Stiffness
Interventions
First Posted Date
2010-06-15
Last Posted Date
2013-11-13
Lead Sponsor
Chinese University of Hong Kong
Target Recruit Count
44
Registration Number
NCT01143987
Locations
🇭🇰

Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, New Territories, Hong Kong

Evaluation of a Cincalcet Suppression Test

Phase 4
Completed
Conditions
Parathyroid Hormone Suppression Test With Cinacalcet
Interventions
First Posted Date
2010-04-14
Last Posted Date
2013-10-16
Lead Sponsor
University Hospital, Rouen
Target Recruit Count
36
Registration Number
NCT01103206
Locations
🇫🇷

University hospital, Rouen, Haute Normandie, France

Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level

Phase 4
Completed
Conditions
Secondary Hyperparathyroidism
Interventions
Drug: control
First Posted Date
2010-04-09
Last Posted Date
2012-06-08
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
66
Registration Number
NCT01101113
Locations
🇰🇷

Hallym University Sacred Hospital, Pyungchon, Korea, Republic of

🇰🇷

Seoul National University Hospital, Seoul, Korea, Korea, Republic of

🇰🇷

Seoul National University Bundang Hospital, Seongnam, Korea, Republic of

and more 4 locations

Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer

Phase 2
Completed
Conditions
Adenocarcinoma of the Prostate
Recurrent Prostate Cancer
Interventions
Other: laboratory biomarker analysis
Procedure: quality-of-life assessment
Other: questionnaire administration
First Posted Date
2010-01-22
Last Posted Date
2018-07-05
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
20
Registration Number
NCT01054079
Locations
🇺🇸

Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients

Phase 3
Terminated
Conditions
Chronic Renal Failure
Hemodialysis
Interventions
First Posted Date
2009-11-11
Last Posted Date
2016-05-16
Lead Sponsor
Centre Hospitalier Universitaire, Amiens
Target Recruit Count
176
Registration Number
NCT01011699
Locations
🇫🇷

ALURAD, Limoges, Limousin, France

🇫🇷

Centre Hospital-Universitaire d'Amiens, Amiens, Picardie, France

🇫🇷

Centre Hospitalier, Cambrai, France

and more 10 locations

Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant

Not Applicable
Terminated
Conditions
Hypophosphatemia
Renal Transplant
Interventions
Drug: Placebo
First Posted Date
2009-11-11
Last Posted Date
2021-04-23
Lead Sponsor
Montefiore Medical Center
Target Recruit Count
40
Registration Number
NCT01011114
Locations
🇺🇸

Montefiore Medical Center, Bronx, New York, United States

Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D

Phase 4
Completed
Conditions
Chronic Kidney Disease
Secondary Hyperparathyroidism
Hemodialysis
Interventions
First Posted Date
2009-09-15
Last Posted Date
2012-06-20
Lead Sponsor
Abbott
Target Recruit Count
272
Registration Number
NCT00977080
Locations
🇺🇸

Site Reference ID/Investigator# 22781, Tempe, Arizona, United States

🇺🇸

Site Reference ID/Investigator# 21144, St. Louis, Missouri, United States

🇺🇸

Site Reference ID/Investigator# 22770, Philadelphia, Pennsylvania, United States

and more 80 locations

Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

Phase 3
Completed
Conditions
Chronic Kidney Disease
Chronic Allograft Nephropathy
Hyperparathyroidism
Kidney Disease
Post Renal Transplantation
Kidney Transplantation
Chronic Renal Failure
Hypophosphatemia
Disordered Mineral Metabolism
End Stage Renal Disease
Interventions
Drug: Placebo
First Posted Date
2009-09-11
Last Posted Date
2018-10-17
Lead Sponsor
Amgen
Target Recruit Count
114
Registration Number
NCT00975000
Locations
🇨🇭

Research Site, Zurich, Switzerland

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy